子宫内膜癌前哨淋巴结定位检出的孤立肿瘤细胞:辅助治疗是否重要?
本单中心前瞻性收集数据研究纳入2010年11月至2015年12月间接受子宫切除、输卵管卵巢切除、淋巴结清扫及前哨淋巴结定位的519例子宫内膜癌患者,其中31例(36%)前哨淋巴结转移为孤立肿瘤细胞。中位随访29个月,孤立肿瘤细胞患者3年无进展生存率为95.5%,与淋巴结阴性(87.6%)和微转移(85.5%)相似,但显著优于宏转移(58.5%)(p=0.0012)。作者认为孤立肿瘤细胞患者预后极好,辅助治疗应基于子宫因素和组织学而非仅依据孤立肿瘤细胞,需更多研究证实。
要点
- 519例中85例(16.4%)前哨淋巴结转移,其中孤立肿瘤细胞31例(36%)。
- 孤立肿瘤细胞患者3年无进展生存率95.5%,与淋巴结阴性87.6%和微转移85.5%相似。
- 孤立肿瘤细胞患者3年无进展生存率显著优于宏转移患者58.5%(p=0.0012)。
核心结论
- 子宫内膜癌前哨淋巴结孤立肿瘤细胞患者预后极好。
- 辅助治疗应基于子宫因素和组织学调整,而非仅依据孤立肿瘤细胞的存在。
- 孤立肿瘤细胞且其他子宫因素低危的患者从额外治疗中可能获益甚微。
- 需要更多研究证实上述结果。
研究设计与样本
- 单中心研究,前瞻性收集2010年11月至2015年12月间接受子宫切除、输卵管卵巢切除、淋巴结清扫及前哨淋巴结定位的子宫内膜癌患者数据。
- 共纳入519例患者。
- 采用Kaplan-Meier法分析无进展生存,log-rank检验进行比较。
主要发现
- 85例(16.4%)发现前哨淋巴结转移,其中宏转移43例(51%)、微转移11例(13%)、孤立肿瘤细胞31例(36%)。
- 孤立肿瘤细胞患者中11例(35%)接受辅助化疗±全盆腔放疗,10例(32%)接受全盆腔放疗,10例(32%)未接受辅助治疗或仅接受阴道近距离放疗。
- 孤立肿瘤细胞患者接受化疗(p=0.0001)和全盆腔放疗(p=0.007)显著少于宏转移患者。
- 中位随访29个月(范围0-67),孤立肿瘤细胞患者3年无进展生存率为95.5%,淋巴结阴性患者为87.6%,微转移患者为85.5%,宏转移患者为58.5%(p=0.0012)。
- 孤立肿瘤细胞患者中仅1/31复发(IB期,7cm癌肉瘤),尽管接受了辅助治疗;子宫内膜样组织学患者无复发(0/28);未接受辅助治疗或仅阴道近距离放疗的患者无复发(0/10)。
临床怎么用
- 本研究中孤立肿瘤细胞未被视为淋巴结阳性。
- 作者认为辅助治疗应基于子宫因素和组织学调整,而非仅依据孤立肿瘤细胞的存在。
- 作者认为孤立肿瘤细胞且其他子宫因素低危的患者从额外治疗中可能获益甚微。
局限性
- 需要更多研究证实上述结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the outcome and the role of adjuvant treatment in the management of patients with endometrial cancer and isolated tumor cells (ITCs) identified by SLN mapping. METHODS: This single center study identified all patients undergoing hysterectomy, salpingo-oophorectomy, lymphadenectomy and SLN mapping for endometrial cancer between November 2010 and December 2015. Data was prospectively collected. Progression-free survival was analyzed according to the Kaplan-Meier method and compared using the log-rank test. RESULTS: A total of 519 patients were included. Overall, 85 patients (16.4%) were found to have SLN metastases of which 43 (51%) were macrometastasis, 11 (13%) micrometastasis (MM) and 31 (36%) ITC. Eleven (35%) of patients with ITCs received adjuvant chemotherapy±whole pelvic radiation therapy (WPRT), 10 (32%) received WPRT, and 10 (32%) received either no adjuvant treatment or vault brachytherapy (VBT) only. ITC patients received significantly less chemotherapy (p=0.0001) and WPRT (p=0.007) compared to patients with macrometastasis. Of note, ITC were not considered node positive in our study. With a median follow-up of 29months (range: 0-67), the progression free survival (PFS) at 3-years for the ITC patients was 95.5%, similar to node negative (87.6%) and micrometastasis patients (85.5%), but statistically better than patients with macrometastasis (58.5%) (p=0.0012). Only 1/31 patient with ITC recurred (IB, 7cm carcinosarcoma) despite adjuvant treatments. None of the ITC patients with endometrioid histology recurred (0/28) and none of the ITC patients who did not receive adjuvant treatment or VBT recurred (0/10). CONCLUSIONS: Patients with endometrial cancer found to have SLN ITCs have an excellent outcome. The use of adjuvant treatment should be tailored to uterine factors and histology and not solely based on the presence of ITCs. Patients with ITCs and otherwise low-risk uterine disease probably derive little benefit from receiving additional treatments. More studies are needed to confirm our results.
引用
- Plante M, Stanleigh J, Renaud MC, et al. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter? Gynecol Oncol. 2017. PMID: 28577885. doi:10.1016/j.ygyno.2017.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。